CURE Epilepsy is not affiliated with, nor has any financial investment in the listed opportunities nor the involved organizations. CURE Epilepsy is not sponsoring nor is directly involved in this project. Should you choose to reach out to the organizations involved with these projects, you would do so independently from CURE Epilepsy.


The STARS Study is testing an inhaler containing an investigational drug to see whether it could help people who experience prolonged epileptic seizures (i.e. lasting more than 3 minutes).

This is a Phase 3, double-blind, randomized, placebo-controlled study to assess the efficacy and safety of Staccato Alprazolam in study participants age 12 years and older with stereotypical prolonged seizures. The primary and secondary outcome measures will focus on treatment success for the treated seizure and recurrence of seizures in the hours following treatment, as well as gathering information on safety and any adverse events.

Learn more and find study sites at the STARS trial website.

See the STARS Participant Brochure. You can also find more information on the trial at clinical trials.gov


PTC Therapeutics and Invitae have partnered to provide PTC Pinpoint Neurotransmitter Disorders Program, a no-cost genetic testing, post-test genetic counseling, and family screening program for individuals of all ages who present with symptoms of neurotransmitter disorders, such as Aromatic L-amino Acid Decarboxylase (AADC) deficiency.

Genetic counseling is available after testing to help you understand your child’s test results. Family testing is available as well for all blood relatives of individuals who undergo testing and are found to have a mutation or change in the gene, all at no cost.

To learn more about PTC Pinpoint Neurotransmitter Disorders Program, please visit https://www.invitae.com/en/PTC-Pinpoint/.

Learn more about clinical trials

Clinical Trials

Clinical Trials

Clinical Trials

Clinical Trials FAQ


    Join our email list for the
    latest epilepsy research news,
    discoveries, and more.